Q8GZ29 · GH315_ARATH
- ProteinIndole-3-acetic acid-amido synthetase GH3.15
- GeneGH3.15
- StatusUniProtKB reviewed (Swiss-Prot)
- Amino acids595 (go to sequence)
- Protein existenceEvidence at protein level
- Annotation score5/5
Function
function
Indole-3-acetic acid-amido (IAA) synthetase that catalyzes the conjugation of amino acids to auxin specifically using the auxin precursor indole-3-butyric acid (IBA) and glutamine and, possibly, cysteine as substrates (PubMed:29462792, PubMed:30315112).
Displays high catalytic activity with the auxinic phenoxyalkanoic acid herbicides 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB) and to some extent 2,4-dichlorophenoxylacetic acid (2,4-D) as substrates, thus conferring resistance to herbicides (PubMed:30315112).
Displays high catalytic activity with the auxinic phenoxyalkanoic acid herbicides 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB) and to some extent 2,4-dichlorophenoxylacetic acid (2,4-D) as substrates, thus conferring resistance to herbicides (PubMed:30315112).
Catalytic activity
- (indol-3-yl)butanoate + L-cysteine + ATP = (indol-3-yl)butanoyl-L-cysteine + AMP + diphosphate + H+
- (indol-3-yl)butanoate + L-glutamine + ATP = (indol-3-yl)butanoyl-L-glutamine + AMP + diphosphate + H+
- 4-(2,4-dichlorophenoxy)butanoate + L-glutamine + ATP = 4-(2,4-dichlorophenoxy)butanoyl-L-glutamine + AMP + diphosphate + H+
Kinetics
KM | SUBSTRATE | pH | TEMPERATURE[C] | NOTES | EVIDENCE | |
---|---|---|---|---|---|---|
556 μM | indole-3-acetic acid | in the presence of ATP glutamine | ||||
3430 μM | indole-3-propionic acid | in the presence of ATP glutamine | ||||
527 μM | indole-3-butyric acid | in the presence of ATP glutamine | ||||
1120 μM | jasmonic acid | in the presence of ATP glutamine | ||||
1780 μM | glutamine | in the presence of ATP indole-3-butyric acid | ||||
2530 μM | glutamine | in the presence of ATP jasmonic acid | ||||
2080 μM | cysteine | in the presence of ATP indole-3-butyric acid | ||||
12300 μM | histidine | in the presence of ATP indole-3-butyric acid | ||||
5670 μM | methionine | in the presence of ATP indole-3-butyric acid | ||||
18600 μM | tyrosine | in the presence of ATP indole-3-butyric acid | ||||
84 μM | ATP | in the presence of glutamine indole-3-butyric acid | ||||
590 μM | 4-(2,4-dichlorophenoxy)butyric acid | in the presence of ATP glutamine | ||||
3790 μM | 2,4-dichlorophenoxylacetic acid | in the presence of ATP glutamine | ||||
970 μM | glutamine | in the presence of ATP 4-(2,4-dichlorophenoxy)butyric acid | ||||
7240 μM | cysteine | in the presence of ATP 4-(2,4-dichlorophenoxy)butyric acid | ||||
9290 μM | histidine | in the presence of ATP 4-(2,4-dichlorophenoxy)butyric acid | ||||
10600 μM | methionine | in the presence of ATP 4-(2,4-dichlorophenoxy)butyric acid | ||||
18400 μM | tyrosine | in the presence of ATP 4-(2,4-dichlorophenoxy)butyric acid | ||||
23200 μM | 2,4,5-trichlorophenoxyacetic acid | in the presence of ATP glutamine | ||||
1130 μM | 4-(4-chloro-2-methylphenoxy)butanoic acid | in the presence of ATP glutamine | ||||
3550 μM | 4-(2-chlorophenoxy)butanoic acid | in the presence of ATP glutamine | ||||
180 μM | 4-(2,6-dimethylphenoxy)butanoic acid | in the presence of ATP glutamine | ||||
14800 μM | 4-(4-methoxyphenoxy)butanoic acid | in the presence of ATP glutamine | ||||
2140 μM | 4-phenoxybutyric acid | in the presence of ATP glutamine | ||||
6000 μM | 4-phenylbutryic acid | in the presence of ATP glutamine | ||||
960 μM | 5-phenylvaleric acid | in the presence of ATP glutamine | ||||
680 μM | 5-(4-fluorophenyl)valeric acid | in the presence of ATP glutamine |
kcat is 0.76 min-1 with indole-3-acetic acid as substrate (in the presence of ATP and glutamine) (PubMed:29462792, PubMed:30315112).
kcat is 10.2 min-1 with indole-3-propionic acid as substrate (in the presence of ATP and glutamine) (PubMed:29462792).
kcat is 9.9 min-1 with indole-3-butyric acid as substrate (in the presence of ATP and glutamine) (PubMed:29462792, PubMed:30315112).
kcat is 4.4 min-1 with jasmonic acid as substrate (in the presence of ATP and glutamine) (PubMed:29462792).
kcat is 17 min-1 with glutamine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 4 min-1 with glutamine as substrate (in the presence of ATP and jasmonic acid) (PubMed:29462792).
kcat is 16 min-1 with cysteine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 21 min-1 with histidine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 13 min-1 with methionine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 25 min-1 with tyrosine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 13 min-1 with ATP as substrate (in the presence of indole-3-butyric acid and glutamine) (PubMed:29462792).
kcat is 11 min-1 with 4-(2,4-dichlorophenoxy)butyric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 1.3 min-1 with 2,4-dichlorophenoxylacetic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 52.3 min-1 with glutamine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 52.5 min-1 with cysteine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 43.1 min-1 with histidine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 27.5 min-1 with methionine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 12 min-1 with tyrosine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 4.3 min-1 with 2,4,5-trichlorophenoxyacetic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 15.6 min-1 with 4-(4-chloro-2-methylphenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 24 min-1 with 4-(2-chlorophenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 5.4 min-1 with 4-(2,6-dimethylphenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 29.8 min-1 with 4-(4-methoxyphenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 16.2 min-1 with 4-phenoxybutyric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 15 min-1 with 4-phenylbutryic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 26.6 min-1 with 5-phenylvaleric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 24 min-1 with 5-(4-fluorophenyl)valeric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 10.2 min-1 with indole-3-propionic acid as substrate (in the presence of ATP and glutamine) (PubMed:29462792).
kcat is 9.9 min-1 with indole-3-butyric acid as substrate (in the presence of ATP and glutamine) (PubMed:29462792, PubMed:30315112).
kcat is 4.4 min-1 with jasmonic acid as substrate (in the presence of ATP and glutamine) (PubMed:29462792).
kcat is 17 min-1 with glutamine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 4 min-1 with glutamine as substrate (in the presence of ATP and jasmonic acid) (PubMed:29462792).
kcat is 16 min-1 with cysteine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 21 min-1 with histidine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 13 min-1 with methionine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 25 min-1 with tyrosine as substrate (in the presence of ATP and indole-3-butyric acid) (PubMed:29462792).
kcat is 13 min-1 with ATP as substrate (in the presence of indole-3-butyric acid and glutamine) (PubMed:29462792).
kcat is 11 min-1 with 4-(2,4-dichlorophenoxy)butyric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 1.3 min-1 with 2,4-dichlorophenoxylacetic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 52.3 min-1 with glutamine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 52.5 min-1 with cysteine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 43.1 min-1 with histidine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 27.5 min-1 with methionine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 12 min-1 with tyrosine as substrate (in the presence of ATP and 4-(2,4-dichlorophenoxy)butyric acid) (PubMed:30315112).
kcat is 4.3 min-1 with 2,4,5-trichlorophenoxyacetic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 15.6 min-1 with 4-(4-chloro-2-methylphenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 24 min-1 with 4-(2-chlorophenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 5.4 min-1 with 4-(2,6-dimethylphenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 29.8 min-1 with 4-(4-methoxyphenoxy)butanoic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 16.2 min-1 with 4-phenoxybutyric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 15 min-1 with 4-phenylbutryic acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 26.6 min-1 with 5-phenylvaleric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
kcat is 24 min-1 with 5-(4-fluorophenyl)valeric acid as substrate (in the presence of ATP and glutamine) (PubMed:30315112).
Features
Showing features for binding site.
Type | ID | Position(s) | Description | |||
---|---|---|---|---|---|---|
Binding site | 97-98 | ATP (UniProtKB | ChEBI) | ||||
Sequence: SS | ||||||
Binding site | 302 | ATP (UniProtKB | ChEBI) | ||||
Sequence: T | ||||||
Binding site | 325 | substrate | ||||
Sequence: F | ||||||
Binding site | 325-330 | ATP (UniProtKB | ChEBI) | ||||
Sequence: FYGSSE | ||||||
Binding site | 332 | substrate | ||||
Sequence: F | ||||||
Binding site | 348 | ATP (UniProtKB | ChEBI) | ||||
Sequence: Y | ||||||
Binding site | 408 | ATP (UniProtKB | ChEBI) | ||||
Sequence: D |
GO annotations
Aspect | Term | |
---|---|---|
Cellular Component | cytosol | |
Molecular Function | ATP binding | |
Molecular Function | glutamine binding | |
Molecular Function | ligase activity | |
Biological Process | auxin conjugate metabolic process |
Keywords
- Molecular function
- Ligand
Enzyme and pathway databases
Names & Taxonomy
Protein names
- Recommended nameIndole-3-acetic acid-amido synthetase GH3.15
- EC number
- Alternative names
Gene names
Organism names
- Strain
- Taxonomic lineageEukaryota > Viridiplantae > Streptophyta > Embryophyta > Tracheophyta > Spermatophyta > Magnoliopsida > eudicotyledons > Gunneridae > Pentapetalae > rosids > malvids > Brassicales > Brassicaceae > Camelineae > Arabidopsis
Accessions
- Primary accessionQ8GZ29
- Secondary accessions
Proteomes
Organism-specific databases
Genome annotation databases
Subcellular Location
UniProt Annotation
GO Annotation
Phenotypes & Variants
Disruption phenotype
No visible phenotype in normal conditions (PubMed:29462792).
Slight reduction in root length when grown on media containing indole-3-butyric acid (IBA) (PubMed:29462792).
Hypersensitivity to the auxinic phenoxyalkanoic acid herbicide 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB) (PubMed:30315112).
Slight reduction in root length when grown on media containing indole-3-butyric acid (IBA) (PubMed:29462792).
Hypersensitivity to the auxinic phenoxyalkanoic acid herbicide 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB) (PubMed:30315112).
Features
Showing features for mutagenesis.
Type | ID | Position(s) | Description | |||
---|---|---|---|---|---|---|
Mutagenesis | 122 | Increased affinity and enhanced catalytic activity leading to improved efficiency toward indole-3-butyric acid. Reduced affinity but increased catalytic activity leading to almost unaffected efficiency toward indole-3-acetic acid. | ||||
Sequence: S → F, I, or L | ||||||
Mutagenesis | 122 | Reduced affinity and altered catalytic activity leading to decreased efficiency toward indole-3-butyric acid. | ||||
Sequence: S → W | ||||||
Mutagenesis | 122 | Reduced affinity but enhanced catalytic activity leading to improved efficiency toward indole-3-butyric acid. Reduced affinity but increased catalytic activity leading to almost unaffected efficiency toward indole-3-acetic acid. | ||||
Sequence: S → Y | ||||||
Mutagenesis | 162 | Increased affinity and enhanced catalytic activity leading to improved efficiency toward indole-3-butyric acid. Slightly increased affinity but normal catalytic activity leading to slightly improved efficiency toward indole-3-acetic acid. | ||||
Sequence: M → V | ||||||
Mutagenesis | 166 | Strongly reduced affinity but enhanced catalytic activity leading to reduced efficiency toward indole-3-butyric acid. Slightly increased affinity and slightly better catalytic activity leading to slightly improved efficiency toward indole-3-acetic acid. | ||||
Sequence: F → V | ||||||
Mutagenesis | 332 | Strongly reduced affinity but normal catalytic activity leading to reduced efficiency toward indole-3-butyric acid. Strongly reduced affinity and slightly better catalytic activity leading to reduced efficiency toward indole-3-acetic acid. | ||||
Sequence: F → V |
Variants
We now provide the "Disease & Variants" viewer in its own tab.
The viewer provides 72 variants from UniProt as well as other sources including ClinVar and dbSNP.
PTM/Processing
Features
Showing features for chain.
Type | ID | Position(s) | Description | |||
---|---|---|---|---|---|---|
Chain | PRO_0000447233 | 1-595 | Indole-3-acetic acid-amido synthetase GH3.15 | |||
Sequence: MLPKFDPTNQKACLSLLEDLTTNVKQIQDSVLEAILSRNAQTEYLRGFLNGQVDKQNFKKNVPVVTYEDIRSYIDRIANGEPSDLICDRPISVLLTSSGTSGGVPKLIPLTTEDLEQRISFSSLYAPLLYKHIDGLSEGKSLIFYFVTRESKTANGLMVRTMVTSFLKSIKQTNSFLWDSLQVSPHAITTCADTTQSMYCQLLCGLLERDNVARLGAPFASSFLKVIKFLEDHWPELCSNIRTGRLSDWITDATCTSGIGKFLTAPNPELASLIEQECSKTSWEAILKRLWPKAKCIESIITGTMAQYIPLLEFYSGGLPLTSSFYGSSECFMGVNFNPLCKPSDVSYTIIPCMGYFEFLEVEKDHQEAGHDPTEKPVVVDLVDVKIGHDYEPVVTTFSGLYRYRVGDVLRATGFYNNAPHFCFVGRQKVVLSIDMDKTYEDDLLKAVTNAKLLLEPHDLMLMDFTSRVDSSSFPGHYVIYWELGSKVKDAKFEPNRDVMEECCFTVEESLDAVYRKGRKNDKNIGPLEIKVVKPGAFDELMNFFLSRGSSVSQYKTPRSVTNEEALKILEANVISEFLSRKIPSWELHELHSGR |
Proteomic databases
Expression
Tissue specificity
Expressed in seedlings, roots, and parts of the siliques.
Developmental stage
Expressed widely in young seedling, including roots, shoots, and cotyledons. In older seedlings, present the primary root, shoots, and cotyledons, but not in the root epidermal cells or root hairs. Later observed in the cotyledons and the shoots, but not in the true leaves. In adult plants, accumulates in the primary root and lateral root tips and in the roots near the root/shoot junction. In mature siliques, confined to the tip of the silique in the style just below the stigma and at the base of the silique in the replum and abscission zone of siliques.
Gene expression databases
Interaction
Protein-protein interaction databases
Structure
Sequence
- Sequence statusComplete
- Length595
- Mass (Da)66,979
- Last updated2003-03-01 v1
- Checksum510294E9B2F5D1B1
Sequence caution
Keywords
- Technical term
Sequence databases
Nucleotide Sequence | Protein Sequence | Molecule Type | Status | |
---|---|---|---|---|
AL163572 EMBL· GenBank· DDBJ | CAB87144.1 EMBL· GenBank· DDBJ | Genomic DNA | Sequence problems. | |
CP002688 EMBL· GenBank· DDBJ | AED91887.1 EMBL· GenBank· DDBJ | Genomic DNA | ||
BT005922 EMBL· GenBank· DDBJ | AAO64857.1 EMBL· GenBank· DDBJ | mRNA | ||
AK117242 EMBL· GenBank· DDBJ | BAC41918.1 EMBL· GenBank· DDBJ | mRNA |